Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.

Calapai F, Mannucci C, McQuain L, Salvo F

Open source

DOI
10.3390/ph16101420
Published
2023 Oct 5
Container
Pharmaceuticals (Basel, Switzerland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ph16101420,
  title = {Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.},
  author = {Calapai F and Mannucci C and McQuain L and Salvo F},
  year = {2023},
  journal = {Pharmaceuticals (Basel, Switzerland)},
  doi = {10.3390/ph16101420},
  url = {https://doi.org/10.3390/ph16101420}
}

RIS

TY  - JOUR
TI  - Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.
AU  - Calapai F
AU  - Mannucci C
AU  - McQuain L
AU  - Salvo F
PY  - 2023
JO  - Pharmaceuticals (Basel, Switzerland)
DO  - 10.3390/ph16101420
UR  - https://doi.org/10.3390/ph16101420
ER  - 

APA

F, C., C, M., L, M., & F, S. (2023). Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph16101420

Source records